Can colchicine prevent recurrence of new-onset acute pericarditis?
Yehuda Adler*, David H Spodick, Ralph Shabetai and Antonio Brucato
Correspondence *Cardiac Rehabilitation Institute, Sheba Medical Centre, Tel-Hashomer 52621, Israel
Email adlery@post.tau.ac.il
This article has no abstract so we have provided the first paragraph of the full text.
Pericarditis accounts for around 5% of all presentations to emergency departments for non-myocardial-infarction-related chest pain;1 it can recur in up to 30% of patients. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the mainstay of therapy for pericarditis, and glucocorticoid treatment should be restricted to severely symptomatic patients who are unresponsive to appropriate NSAID doses.1, 2 In this study, Imazio et al. showed that, when compared with conventional therapy, colchicine plus conventional therapy for the treatment of the first episode of acute pericarditis decreased the rate of recurrence at 18 months (32.3% vs 10.7%) and reduced symptom persistence at 72 h (36.7% vs 11.7%). Moreover, they found that corticosteroid therapy favored recurrences.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
